tbuckley/cabot-search huggingface dataset:
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Authors: Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld, Fredrik Schjesvold, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Anna Nikolayeva, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Meletios-Athanasios Dimopoulos, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Vladimir Maisnar, Gabor Mikala, Laura Rosinol, Tatiana Konstantinova, Antonio Lazzaro, Anna Marina Liberati, Anargyros Symeonidis, Moshe Gatt, Arpad Illes, Haifaa Abdulhaq, Moez Dungarwalla, Sebastian Grosicki, Roman Hajek, Xavier Leleu, Alexander Myasnikov, Paul G. Richardson, Irit Avivi, Dries Deeren, Mercedes Gironella, Miguel Teodoro Hernandez-Garcia, Joaquin Martinez Lopez, Muriel Newinger-Porte, Paz Ribas, Olga Samoilova, Eric Voog, Mario Arnao-Herraiz, Estrella Carrillo-Cruz, Paolo Corradini, Jyothi Dodlapati, Miquel Granell Gorrochategui, Shang-Yi Huang, Matthew Jenner, Lionel Karlin, Jin Seok Kim, Agnieszka Kopacz, Nadezhda Medvedeva, Chang-Ki Min, Roberto Mina, Katrin Palk, Ho-Jin Shin, Sang Kyun Sohn, Pieter Sonneveld, Jason Tache, Achilles Anagnostopoulos, Jose-Maria Arguiñano, Michele Cavo, Joanne Filicko, Margaret Garnes, Janusz Halka, Kathrin Herzog-Tzarfati, Natalia Ipatova, Kihyun Kim, Maria-Theresa Krauth, Irina Kryuchkova, Mihaela Cornelia Lazaroiu, Mario Luppi, Andrei Proydakov, Alessandro Rambaldi, Milda Rudzianskiene, Su-Peng Yeh, Maria Magdalena Alcalá-Peña, Adrian Alegre Amor, Hussain Alizadeh, Maurizio Bendandi, Gillian Brearton, Randall Brown, Jim Cavet, Najib Dally, Miklos Egyed, José Ángel Hernández-Rivas, Ain Kaare, Jean-Michel Karsenti, Janusz Kloczko, William Kreisle, Je-Jung Lee, Wojciech Legiec, Sigrid Machherndl-Spandl, Sudhir Manda, Maria-Victoria Mateos, Ivan Moiseev, Jan Moreb, Zsolt Nagy, Santosh Nair, Albert Oriol-Rocafiguera, Michael Osswald, Paula Otero-Rodriguez, Valdas Peceliunas, Torben Plesner, Philippe Rey, Giuseppe Rossi, Don Stevens, Celia Suriu, Corrado Tarella, Anke Verlinden, Alain Zannetti
Journal: The Lancet Haematology (2022)
Abstract P046: Sex Hormone Levels and 10-Year Change in N-Terminal Pro-Brain Natriuretic Peptide Among Men and Post-Menopausal Women: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Wendy Ying, Di Zhao, Pamela Ouyang, Dhananjay Vaidya, Chiadi E Ndumele, Kavita Sharma, Vinita Subramanya, Eliseo Guallar, Susan R Heckbert, Joao A Lima, Christopher R deFilippi, Matthew J Budoff, Wendy S Post, Erin D Michos
Journal: Circulation (2018)

Background: The risk of cardiovascular disease (CVD) differs between men and women, and sex hormones are thought to play a key role. N-terminal pro-brain natriuretic peptide (NT-proBNP) is a sensitive biomarker of ventricular wall stress and a strong predictor of incident cardiovascular disease (CVD) and heart failure (HF). It can thus be seen as an early marker of CVD. We evaluated whether sex hormones levels were associated with change in NT-proBNP concentrations over 10 years in MESA. Methods: We studied 2348 men and 2041 post-menopausal women. Serum testosterone (T), estradiol, dehydroepiandrosterone (DHEA), and sex hormone binding globulin (SHBG) were measured at Exam 1 (2000-02); free T and bioavailable T were calculated. NT-proBNP was measured by Roche assay at Exam 1, plus Exam 3 (2004-05) and/or Exam 5 (2010-12). Multivariable-adjusted linear mixed effects models were used to study associations between sex hormone levels and change in NT-proBNP over an approximately 10-year period. Results: Mean (SD) age (years) at baseline was 65 (9) for women and 62 (10) for men. Women had higher NT-proBNP than men (median 76.6 vs 37.1 pg/ml). Among women, after adjusting for demographic, socioeconomic, and CVD risk factors, higher total T, bioavailable T, and free T were independently associated with a greater increase in NT-proBNP over 10 years, whereas estradiol and SHBG were inversely associated with change in NT-proBNP ( Table ). When sex hormones were analyzed together in the same model, total T was positively associated and SHBG was inversely associated with change in NT-proBNP. In men, higher estradiol was associated with greater 10-year increase in NT-proBNP. These associations were preserved after excluding individuals with ejection fraction &lt;50%. Conclusion: A more androgenic sex hormone profile in post-menopausal women and a more estrogenic profile in men were independently associated with 10-year change in NT-proBNP levels. Sex hormone patterns may thus explain in part sex differences in the development of CVD and HF.
Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A single institution experience.
Authors: Winston Wong, Jacob K.R. Jamison, Michael S. May, Alissa Michel, Tristan Lee, David Manrique, Alexander Raufi, Samuel M Pan, Rachael A Safyan, David Paul Horowitz, Beth Schrope, Michael Kluger, Lisa A. Kachnic, Jianhua Hu, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji
Journal: Journal of Clinical Oncology (2022)

565 Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a minority of patients (pts) eligible for curative resection. Currently, systemic treatment options for down-staging pts with borderline resectable or locally advanced PDAC is extrapolated from the metastatic setting and modified FOLFIRINOX (FFX) +/- radiation (RT) is the most widely used regimen. Herein, we report the outcomes of combination gemcitabine, docetaxel, and capecitabine (GTX) +RT as compared to FFX +RT in the neoadjuvant (NA) setting via a single institution retrospective cohort review. Methods: We retrospectively reviewed the outcomes of pts with PDAC who underwent surgical resection at Columbia University Irving Medical Center (CUIMC) between 2011-2020. We evaluated demographics, treatment, clinical, surgical, and pathological outcomes. Statistical analysis includes Kaplan-Meier analysis and paired t-tests. Results: We reviewed 717 pts who underwent surgical resection at CUIMC of which 227 pts were confirmed to have received NA chemotherapy. Of those 227 patients, 133 pts also received RT. In total, 39 pts received GTX+RT and 42 pts received FFX+RT. Median age at diagnosis of pts who received NA GTX+RT or FFX+RT was 65 and 63 years, respectively. All pts were AJCC stage III at diagnosis and ECOG 0 or 1. There was a significantly greater percentage of pts who achieved R0 resection after GTX+RT as compared to FFX+RT, 35 (89.7%) vs 29 (69.0%), respectively (p=0.022). Significantly more pts achieved N0 lymph node status after GTX+RT as compared to FFX+RT, 29 (74.4%) vs 22 (52.4%), respectively (p=0.041). No statistically significant difference was detected in recurrence-free survival (RFS) or median overall survival (mOS) in pts who received GTX+RT and achieved R0 resection as compared to FFX+RT. See Table for summary. Conclusions: GTX appears to be a viable and active NA regimen in Stage III PDAC. In our small cohort study, more patients who received GTX+RT achieved R0 resection and N0 status as compared to FFX+RT. No difference in survival was detected but this may be due to inadequate power or choice of subsequent therapies. Larger prospective studies evaluating GTX+RT as an alternative treatment in the NA setting are warranted.[Table: see text]
Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid–season results
Authors: R  G Pebody, F Warburton, J Ellis, N Andrews, C Thompson, B von Wissmann, H K Green, S Cottrell, J Johnston, S de Lusignan, C Moore, R Gunson, C Robertson, J McMenamin, M Zambon
Journal: Eurosurveillance (2015)

In 2014/15 the United Kingdom experienced circulation of influenza A(H3N2) with impact in the elderly. Mid-season vaccine effectiveness (VE) shows an adjusted VE of 3.4% (95% CI: ?44.8 to 35.5) against primary care consultation with laboratory-confirmed influenza and ?2.3% (95% CI: ?56.2 to 33.0) for A(H3N2). The low VE reflects mismatch between circulating viruses and the 2014/15 northern hemisphere A(H3N2) vaccine strain. Early use of antivirals for prophylaxis and treatment of vulnerable populations remains important.
260. Long-Term Neurologic Correction in the Pompe Disease Mice By Intrathecal Gene Therapy
Authors: Juliette Hordeaux, Laurence Dubreil, Cynthia Robveille, Quentin Pascal, Johan Deniaud, Mireille Ledevin, Candice Babarit, F Jamme, C Huchet, C Caillaud, Marie-Anne Colle
Journal: Molecular Therapy (2014)
COVID-19–Related Life Experiences, Outdoor Play, and Long-term Adiposity Changes Among Preschool- and School-Aged Children in Singapore 1 Year After Lockdown
Authors: Ka Kei Sum, Shirong Cai, Evelyn Law, Bobby Cheon, Geoffrey Tan, Evelyn Loo, Yung Seng Lee, Fabian Yap, Jerry Kok Yen Chan, Mary Daniel, Yap Seng Chong, Michael Meaney, Johan Eriksson, Jonathan Huang
Journal: JAMA Pediatrics (2022)

Despite the potential for COVID-19 infection control-related events to have an effect on child well-being, comprehensive assessments of postlockdown changes and persistent outcomes are lacking.
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
Authors: Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O’Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Wei Guo, Ellie Im, Sybil Zildjian, Xinwei Han, Tao Duan, Jennifer Veneris, Bhavana Pothuri
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from patients with endometrial cancer (EC) participating in a phase I trial of single-agent dostarlimab. Methods GARNET, an ongoing, single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumors, is being undertaken at 123 sites. Two cohorts of patients with EC were recruited: those with dMMR/MSI-H disease (cohort A1) and those with proficient/stable (MMRp/MSS) disease (cohort A2). Patients received dostarlimab 500 mg every 3 weeks for 4 cycles, then dostarlimab 1000 mg every 6 weeks until disease progression. The primary endpoints were objective response rate (ORR) and duration of response (DOR) per RECIST V.1.1, as assessed by blinded independent central review. Results Screening began on April 10, 2017, and 129 and 161 patients with advanced EC were enrolled in cohorts A1 and A2, respectively. The median follow-up duration was 16.3 months (IQR 9.5–22.1) for cohort A1 and 11.5 months (IQR 11.0–25.1) for cohort A2. In cohort A1, ORR was 43.5% (95% CI 34.0% to 53.4%) with 11 complete responses and 36 partial responses. In cohort A2, ORR was 14.1% (95% CI 9.1% to 20.6%) with three complete responses and 19 partial responses. Median DOR was not reached in either cohort. In the combined cohorts, the majority of treatment-related adverse events (TRAEs) were grade 1–2 (75.5%), most commonly fatigue (17.6%), diarrhea (13.8%), and nausea (13.8%). Grade≥3 TRAEs occurred in 16.6% of patients, and 5.5% discontinued dostarlimab because of TRAEs. No deaths were attributable to dostarlimab. Conclusion Dostarlimab demonstrated durable antitumor activity in both dMMR/MSI-H (ORR 43.5%) and MMRp/MSS EC (ORR 14.1%) with a manageable safety profile. Trial registration number NCT02715284 .
Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
Authors: Aakash Desai, Caleb Scheckel, Chelsee J. Jensen, Jacob Orme, Colt Williams, Nilay Shah, Konstantinos Leventakos, Alex A. Adjei
Journal: JAMA Network Open (2022)

Oncology drug prices are a determinant of health disparities in the US and worldwide. Several new therapeutic agents for non-small cell lung cancer (NSCLC) have become available on the US market over the past decade. Although increased competition typically produces lower prices, competition among brand-name oncology drugs has not resulted in lower prices.To assess price changes in class-specific brand-name medications used to treat metastatic NSCLC in the US from 2015 to 2020.This cross-sectional study, conducted from August 13, 2015, to August 13, 2020, used data from the Micromedex Red Book and Medi-Span Price Rx databases. The study sample was limited to 17 brand-name medications used to treat metastatic NSCLC that were available for purchase before January 1, 2019.The main outcomes were trends over time in average wholesale prices and wholesale acquisition cost unit prices and the correlation in price among the multiple brand-name medications within each therapeutic class (immune checkpoint inhibitors, epidermal growth factor receptor inhibitors, anaplastic lymphoma kinase inhibitors, ROS1 inhibitors, BRAF inhibitors, and MEK inhibitors), measured using the Pearson correlation coefficient. The compounded annual growth rates of different medication costs were compared with the annual inflation rate and the consumer price index for prescription drugs.For all drug classes, the Pearson correlation coefficient approached 1.0, indicating an increase in drug list prices despite within-class drug competition. The median Pearson correlation coefficient values were 0.964 (range, 0.951-0.994) for immune checkpoint inhibitors, 0.898 (range, 0.665-0.950) for epidermal growth factor receptor inhibitors, 0.999 (range, 0.982-0.999) for anaplastic lymphoma kinase inhibitors, and 0.999 for BRAF and MEK inhibitors. The median compounded annual growth rates for most drug costs were higher than the annual inflation rate and consumer price index for prescription drugs: 1.81% (range, 1.29%-2.13%) for immune checkpoint inhibitors, 2.56% (range, 2.38%-5.26%) for epidermal growth factor receptor inhibitors, 2.46% (range, 1.75%-4.66%) for anaplastic lymphoma kinase and ROS1 inhibitors, and 3.06% (range, 0%-3.06%) for BRAF and MEK inhibitors.In this cross-sectional study, prices of brand-name medications for treatment of NSCLC increased in the US from 2015 to 2020 without evidence of price competition, raising concern about the affordability of promising oncology drugs. These findings suggest that drug pricing reform is needed.
The Authors Reply:
Authors: Litten Bertelsen, Søren Zöga Diederichsen, Ketil Jørgen Haugan, Axel Brandes, Claus Graff, Derk Krieger, Christian Kronborg, Lars Køber, Dana C. Peters, Morten Salling Olesen, Søren Højberg, Niels Vejlstrup, Jesper Hastrup Svendsen
Journal: JACC. Cardiovascular imaging (2021)
THE IMPACT OF LIFELONG EXERCISE TRAINING “DOSE” ON THE VENTRICULAR-ARTERIAL COUPLING
Authors: Michinari Hieda, Erin Howden, Satyam Sarma, Takashi Tarumi, Dean Palmer, Justin Lawley, Christopher Hearon, Ashley Hardin, Qi Fu, Rong Zhang, Benjamin D. Levine
Journal: Journal of the American College of Cardiology (2017)
Global prevalence of digital addiction in general population: A systematic review and meta-analysis
Authors: Shi-Qiu Meng, Jia-Lu Cheng, Yang-Yang Li, Xiao-Qin Yang, Jun-Wei Zheng, Xiang-Wen Chang, Yu Shi, Yun Chen, Lin Lu, Yan Sun, Yan-Ping Bao, Jie Shi
Journal: Clinical Psychology Review (2022)
A study into the drug dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis
Journal: British Journal of Dermatology (2020)

Atopic dermatitis (AD), a long-lasting skin disease characterized by intense itching and dry, red, swollen and cracked skin, affects between 2% and 10% of Japanese adults.In Japan, patients with moderate-to-severe or very severe AD have limited treatment options, most with unwanted side effects.There is a need for therapies that provide safe and effective long-term control.The underlying mechanism of AD may differ between Asian and Western patients, and this study aimed to evaluate dupilumab, a drug that blocks key molecules that cause AD, in Japanese patients with moderate-to-severe AD.The authors studied Japanese patients from three international, placebo-controlled clinical trials of dupilumab.Of the 1,597 adults with moderate-to-severe AD in those trials ("all patients"), 250 were Japanese.The investigators measured the effects of dupilumab treatment for 16 weeks or one year on the signs (what a clinician observes) and symptoms (what a patient feels) of AD.At the start of each trial, Japanese patients generally had more severe AD than all patients.Nevertheless, dupilumab significantly improved signs and symptoms of AD (including itch) compared with placebo (dummy drug) in the Japanese patients and was as well tolerated in the Japanese patients as in all patients; dupilumab was more likely than placebo to be associated with injection-site reaction or conjunctivitis ("pinkeye").Compared with placebo, dupilumab reduced the amount of substances in the blood that are generally increased in patients with AD.The investigators concluded that, similar to all patients, dupilumab is effective and well tolerated in Japanese patients with moderate-to-severe AD.
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin
Authors: Zehao Wang, Lu Yang, Peng Wu, Xing Li, Yuhui Tang, Xueqi Ou, Yue Zhang, Xiangsheng Xiao, Jin Wang, Hailin Tang
Journal: Molecular Cancer (2022)

Metastasis causes the majority of cancer-related deaths worldwide. Increasing studies have revealed that circRNAs are associated with the carcinogenesis and metastasis of many cancers. Nevertheless, the biological mechanisms of circRNAs in breast cancer (BC) liver metastasis remain extremely ambiguous.In this study, we identified circROBO1 from three pairs of primary BC and metastatic liver sites by RNA sequencing. FISH assays and RT-qPCR were conducted to validate the existence and expression of circROBO1. The oncogenic role of circROBO1 was demonstrated both in vitro and in vivo. Western blot, ChIP, RIP, RNA pull-down, and dual-luciferase reporter assays were used to confirm the interaction of the feedback loop among circROBO1, miR-217-5p, KLF5, and FUS. Meanwhile, the regulation of selective autophagy was investigated by immunofluorescence, CoIP, and western blot.In this study, upregulated expression of circROBO1 was found in BC-derived liver metastases and was correlated with poor prognosis. Knockdown of circROBO1 strikingly inhibited the proliferation, migration, and invasion of BC cells, whereas overexpression of circROBO1 showed the opposite effects. Moreover, overexpression of circROBO1 promoted tumor growth and liver metastasis in vivo. Further research revealed that circROBO1 could upregulate KLF5 by sponging miR-217-5p, allowing KLF5 to activate the transcription of FUS, which would promote the back splicing of circROBO1. Therefore, a positive feedback loop comprising circROBO1/KLF5/FUS was formed. More importantly, we found that circROBO1 inhibited selective autophagy of afadin by upregulating KLF5.Our results demonstrated that circROBO1 facilitates the carcinogenesis and liver metastasis of BC through the circROBO1/KLF5/FUS feedback loop, which inhibits the selective autophagy of afadin by suppressing the transcription of BECN1. Therefore, circROBO1 could be used not only as a potential prognostic marker but also as a therapeutic target in BC.
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy
Authors: Mitchell S. Anscher, Shaily Arora, Chana Weinstock, Anup Amatya, Pradeep Bandaru, Chad Tang, Andrew T. Girvin, Mallorie H. Fiero, Shenghui Tang, Rachael Lubitz, Laleh Amiri-Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver
Journal: JAMA Oncology (2022)

<h3>Importance</h3> Immune checkpoint inhibitors (ICIs) and radiation therapy (RT) are widely used to treat various cancers, but little data are available to guide clinicians on ICI use sequentially with RT. <h3>Objective</h3> To assess whether there is an increased risk of serious adverse events (AEs) associated with RT given within 90 days prior to an ICI. <h3>Design, Setting, and Participants</h3> Individual patient data were pooled from 68 prospective trials of ICIs submitted in initial or supplemental licensing applications in the US Food and Drug Administration (FDA) databases through December 2019. Two cohorts were generated: (1) patients who received RT within the 90 days prior to beginning ICI therapy and (2) those who did not receive RT within the 90 days prior to beginning ICI therapy, and AE frequencies were determined. A 1:1 propensity score–matched analysis was performed. <h3>Interventions</h3> All patients received an ICI (atezolizumab, avelumab, cemiplimab, durvalumab, ipilimumab, nivolumab, or pembrolizumab); 1733 received RT within the 90 days prior to starting ICI therapy, and 13 956 did not. <h3>Main Outcomes and Measures</h3> The primary outcome was frequency and severity of AEs. Incidence of AEs was compared descriptively between participants who did vs did not receive RT in the propensity score–matched set. Because all analyses are exploratory (ie, not preplanned and no alpha allocated), assessment for statistical significance of the differences between groups was not considered appropriate. <h3>Results</h3> A total of 25 469 patients were identified; 8634 were excluded because they lacked comparators who had received RT (n = 976), did not receive an ICI (n = 4949), received RT outside of the target window (n = 2338), or had missing data in 1 or more variables used in the propensity analysis (n = 371), leaving 16 835 patients included in the analysis. The majority were younger than 65 years (9447 [56.1%]), male (10 459 [62.1%]), and White (13 422 [79.7%]). Patients receiving RT had generally similar rates of AEs overall to those patients who did not receive RT. The average absolute difference in rates across the AEs was 1.2%, and the difference ranged from 0% for neurologic AEs to 8% for fatigue. No difference in grade 3 to 4 AEs was observed between the 2 groups (absolute difference ranged from 0.01% to 2%). These findings persisted after propensity score matching. <h3>Conclusions and Relevance</h3> In this pooled analysis, administration of an ICI within 90 days following RT did not appear to be associated with an increased risk of serious AEs. Thus, it would appear to be safe to administer an ICI within 90 days of receiving RT. These findings should be confirmed in future prospective trials.
Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic
Authors: Bethany L. Gottesman, Justin Yu, Carina Tanaka, Christopher A. Longhurst, Jane J. Kim
Journal: JAMA Pediatrics (2022)

SARS-CoV-2 Infections and Presymptomatic Type 1 Diabetes Autoimmunity in Children and Adolescents From Colorado, USA, and Bavaria, Germany
P3.01-021 A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China
Authors: Y. Cheng, Y. Wang, J. Zhao, Y. Liu, H. Gao, K. Ma, S. Zhang, H. Xin, J. Liu, C. Han, Z. Zhu, Y. Wang, J. Chen, F. Wen, J. Li, J. Zhang, Z. Zheng, Z. Dai, H. Piao, X. Li, Y. Li, M. Zhong, R. Ma, Y. Zhuang, Y. Xu, Z. Qu, H. Yang, C. Pan, F. Yang, D. Zhang, B. Li
Journal: Journal of Thoracic Oncology (2017)